Precise diagnosis, prevention and treatment of familial cardiomyopathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000035627

Enrollment

Unknown

Registered

2020-08-15

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

familial cardiomyopathy

Interventions

FCM patients (G+/P+), subclinical FCM pathogenic gene carriers (G+/P-):Nil

Healthy family members without pathogenic genes (G-/P-):Nil

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Unexplained heart cavity enlargement, with or without reduced systolic function; 2. Myocardial hypertrophy of unknown cause; 3. Severe arrhythmia of unknown cause, including ventricular tachycardia, ventricular fibrillation, atrial fibrillation, frequent ventricular premature beats, frequent atrial premature beats, second-degree and above atrioventricular block; 4. Have a family history of cardiomyopathy or severe arrhythmia.

Exclusion criteria

Exclusion criteria: 1. Ischemic cardiomyopathy; 2. Hypertension and heart disease; 3. Severe valvular disease; 4. Those who are difficult to follow up.

Design outcomes

Primary

Measure	Time frame
Cardiovascular disease-related deaths, including sudden death;Heart failure related to heart transplantation, ventricular assist device implantation, rehospitalization and treatment plan enhancement;	—

Countries

China

Contacts

Public ContactXian-Hong Shu

Zhongshan Hospital, Fudan University

shu.xianhong@zs-hospital.sh.cn+86 13681973611

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026